Physician profile
John M Watson
NPI 1366460347
$763.41
in general payments reported to CMS, 2019-2025
9 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.15 · 2021: $20.27 · 2022: $26.42 · 2023: $213 · 2024: $285 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.18 | 2022-2025 | Vraylar, Viberzi, Linzess |
| Pfizer INC. | $96.13 | 2020-2025 | |
| Astellas Pharma US INC | $78.12 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $56.86 | 2024-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Astrazeneca Pharmaceuticals LP | $37.89 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $22.69 | 2025 | Eliquis |
| Novo Nordisk INC | $21.66 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $21.04 | 2025 | |
| Dexcom, INC. | $16.84 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.